Latigo Biotherapeutics (NASDAQ:LTGO) Stock Rating Upgraded by Leerink Partners

Latigo Biotherapeutics (NASDAQ:LTGO) was upgraded by research analysts at Leerink Partners to a “strong-buy” rating in a report issued on Tuesday, Zacks reports.

Other research analysts also recently issued reports about the company. Wall Street Zen raised Latigo Biotherapeutics to a “hold” rating in a research note on Saturday, August 15th. Jefferies Financial Group started coverage on shares of Latigo Biotherapeutics in a research note on Tuesday. They issued a “buy” rating and a $50.00 price target on the stock. Guggenheim assumed coverage on shares of Latigo Biotherapeutics in a report on Tuesday. They issued a “buy” rating and a $50.00 price target for the company. Finally, The Goldman Sachs Group assumed coverage on shares of Latigo Biotherapeutics in a research report on Tuesday. They set a “buy” rating and a $73.00 price objective for the company. Four analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Strong Buy” and an average price target of $52.25.

Latigo Biotherapeutics Price Performance

NASDAQ LTGO opened at $22.26 on Tuesday. Latigo Biotherapeutics has a twelve month low of $17.22 and a twelve month high of $25.93.

Insider Activity at Latigo Biotherapeutics

In other news, major shareholder Foresite Capital Management V, purchased 140,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the transaction, the insider owned 2,008,024 shares of the company’s stock, valued at $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director James B. Tananbaum acquired 140,000 shares of Latigo Biotherapeutics stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the purchase, the director owned 2,008,024 shares in the company, valued at $36,144,432. The trade was a 7.49% increase in their position. The SEC filing for this purchase provides additional information.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.